Developer docs
API playgroundTry for free, no card

Search company profiles

Sypharma

Full company profile

uuid000ttst

Namestring
Sypharma
Legal namestring
Sypharma Pty Ltd
Websiteurl
sypharma.com.au
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Sypharma Pty Ltd is an Australian specialty contract development and manufacturing organization (CDMO) founded in 2005 and headquartered in Dandenong, Victoria. The company delivers integrated pharmaceutical development and manufacturing services to innovative biotech developers, supporting clients from early-stage formulation and analytical development through scale-up, process validation, and commercial launch across a range of dosage forms.

Sypharma's core capabilities span aseptic fill-and-finish, terminal sterilization, single-use manufacturing for clinical trial injectables, intravenous fluid manufacturing, and non-sterile GMP excipient manufacturing (powder, liquid, and cream filling). Underlying technology is anchored by single-use manufacturing platforms that reduce contamination risk and enable rapid changeovers, complemented by in-house Chemistry and Microbiology quality-control laboratories that compress testing turnaround. The facility operates under cGMP with TGA, FDA, ISO 13485, and APVMA accreditations, allowing Sypharma to supply Australia and export markets. A separate Sykes Vet International sub-brand addresses veterinary pharmaceutical manufacturing under APVMA oversight.

The business model is B2B contract manufacturing: services are scoped and priced per engagement, with no publicly disclosed pricing. Revenue streams include full-service CDMO engagements, aseptic fill-and-finish, terminal sterilization, custom buffer and CIP solutions, IV fluid manufacturing, and non-sterile manufacturing. The company is privately held, founder/independently owned, with no disclosed institutional investors or funding rounds. Go-to-market is direct enterprise sales targeting biotech and vaccine developers, exemplified by long-standing partnerships with Vaxine Pty Ltd and the University of Queensland for COVID-19 vaccine candidates, a manufacturing collaboration with SCHOTT, and participation in the 2021 Genetis vaccine hub with Technovalia and BioNet.

Short descriptiontext

Sypharma is an Australian specialty CDMO providing aseptic fill-and-finish, terminal sterilization, IV fluid, and single-use manufacturing services to innovative biotech developers across global regulated markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDandenong, Australia
HQ citystring
Dandenong
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, aseptic fill finish, biopharmaceutical CDMO services, vaccine manufacturing services, intravenous fluid production
Industry4 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing (CDMO)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Full-service CDMO providing integrated services including new drug development, early stage formulation, analytical development, scale-up, process validation, and commercial manufacturing for various dosage forms.

sypharma.com.au
2Aseptic Fill & Finish
TypeProfessional Services
Description

Manufacturing services for aseptic filling of pharmaceutical products including clinical trial injectables and commercial supplies.

sypharma.com.au
3Terminal Sterilization
TypeProfessional Services
Description

Terminal sterilization manufacturing services for pharmaceutical products requiring this production method.

sypharma.com.au
4Custom Buffer & CIP Solutions
TypeProfessional Services
Description

Custom formulation and cleaning solutions for pharmaceutical manufacturing.

sypharma.com.au
5IV Fluid Manufacturing
TypeProfessional Services
Description

Precision manufacturing of intravenous fluids for clinical and commercial use.

sypharma.com.au
6Non-Sterile Manufacturing
TypeProfessional Services
Description

GMP-grade excipient manufacturing for pharmaceutical and biopharmaceutical formulation, including powder, liquid and cream filling lines.

sypharma.com.au
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Sykes Vet International
Description

Veterinary pharmaceutical manufacturing services offered by Sypharma.

sypharma.com.au
Core offering1 text field

Sypharma is an Australian specialty contract development and manufacturing organization (CDMO) providing integrated pharmaceutical development and manufacturing services. Its core offerings include aseptic fill and finish, terminal sterilization, single-use manufacturing for clinical injectables, GMP intravenous (IV) fluid manufacturing, non-sterile excipient manufacturing, and custom buffer and CIP solutions, delivered to innovative biotech and vaccine developers across global markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 8 million doses of SpikoGen vaccine safely delivered
Product overview1 text field

Sypharma is an Australian speciality contract development manufacturing organization (CDMO) offering integrated pharmaceutical development and manufacturing services. The portfolio includes core manufacturing services (Aseptic Fill & Finish, Terminal Sterilization, Single Use Manufacturing, Intravenous Fluid Manufacturing, Non-Sterile Manufacture), custom formulation solutions (Custom Buffer & CIP Solutions), veterinary products (Sykes Vet International), and in-house quality control laboratories. These services span the full drug development lifecycle from discovery through commercialization.

Product and service7 records
1Aseptic Fill & Finish
CategoryContract Manufacturing Services
Description

Sterile aseptic filling and finishing services for pharmaceutical products, including clinical trial injectables and commercial supplies, conducted under cGMP conditions for biotech and pharmaceutical clients.

2Terminal Sterilization
CategoryContract Manufacturing Services
Description

Terminal sterilization manufacturing services for pharmaceutical products that require terminal sterilization as part of their production method, ensuring product safety and regulatory compliance.

3Custom Buffer & CIP Solutions
CategoryContract Manufacturing Services
Description

Custom formulation of buffer solutions and clean-in-place (CIP) solutions to support pharmaceutical manufacturing operations for client manufacturing processes.

4Sykes Vet International
CategoryVeterinary Pharmaceutical Manufacturing
Description

Veterinary pharmaceutical manufacturing services operated under the Sykes Vet International sub-brand, covering GMP manufacturing of veterinary medicines and related products.

5Single-Use Manufacturing
CategoryContract Manufacturing Services
Description

Single-use manufacturing solutions for clinical trial injectables, offering flexible, contamination-free GMP production with reduced changeover time, lower contamination risk, cost savings, and faster time to market.

6Intravenous Fluid Manufacturing
CategoryContract Manufacturing Services
Description

GMP manufacture of intravenous (IV) fluids for clinical and commercial use, delivered via automated systems to ensure precision, sterility, and quality at scale for pharmaceutical clients.

7Non-Sterile Manufacture
CategoryContract Manufacturing Services
Description

GMP-grade non-sterile excipient manufacturing supporting pharmaceutical and biopharmaceutical formulation, with powder, liquid, and cream filling lines delivering consistent quality and regulatory compliance.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-30
Description

Partnership for manufacture of COVAX-19 and SpikoGen COVID-19 vaccines. Sypharma performed fill and finish of Vaxine's recombinant spike protein vaccine and manufactured Advax adjuvant products. First Australian-developed Covid-19 vaccine to enter human trials.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest CDMO with broad aseptic fill-finish, mammalian and microbial biologics, and sterile manufacturing capabilities — competing with Sypharma for biotech and vaccine programs but at vastly larger scale.

TypeBroad incumbent
Description

Global CDMO with sterile fill-finish, clinical and commercial manufacturing, and packaging services — competing for similar biotech clients at larger scale.

TypeBroad incumbent
Description

Swiss CDMO with aseptic fill-finish, terminal sterilization and API manufacturing — offers overlapping capabilities with Sypharma's sterile small-molecule drug product services.

TypeBroad incumbent
Description

Large global CDMO offering aseptic fill-finish, sterile manufacturing and integrated development across biologics and small molecules — operates at significantly greater scale and geographic reach than Sypharma.

5Recipharm
TypeBroad incumbent
Description

European CDMO with sterile fill-finish, biopharmaceuticals and vaccine manufacturing — comparable service portfolio with much larger international footprint.

TypeDirect peer
Description

Portugal-headquartered specialty CDMO with strong aseptic fill-finish, terminal sterilization and integrated drug development services — directly comparable to Sypharma's core service mix across small-molecule and biologic injectables.

TypeBroad incumbent
Description

German-based CDMO with solid, semi-solid and sterile injectable manufacturing capabilities — overlaps with Sypharma's small-molecule drug product and aseptic fill-finish offerings.

TypeDirect peer
Description

German CDMO specializing in vaccines, biotech and aseptic fill-finish — comparable to Sypharma on vaccine/biologics focus, cGMP manufacturing and pandemic-response capabilities.

TypeBroad incumbent
Description

Operates the Patheon CDMO network offering aseptic fill-finish, biologics and small-molecule drug product services — a broad incumbent competing with Sypharma for global biotech manufacturing programs.

10Luina Bio
TypeDirect peer
Description

Australian cGMP CDMO offering biologics manufacturing, aseptic fill-finish and vaccine development — the closest domestic peer to Sypharma in scale, capability set and regulatory positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sypharma

Pharmaceutical Contract Manufacturing (CDMO)sypharma.com.au

Sypharma is an Australian specialty CDMO providing aseptic fill-and-finish, terminal sterilization, IV fluid, and single-use manufacturing services to innovative biotech developers across global regulated markets.

What Sypharma does

Sypharma Pty Ltd is an Australian specialty contract development and manufacturing organization (CDMO) founded in 2005 and headquartered in Dandenong, Victoria. The company delivers integrated pharmaceutical development and manufacturing services to innovative biotech developers, supporting clients from early-stage formulation and analytical development through scale-up, process validation, and commercial launch across a range of dosage forms.

Sypharma's core capabilities span aseptic fill-and-finish, terminal sterilization, single-use manufacturing for clinical trial injectables, intravenous fluid manufacturing, and non-sterile GMP excipient manufacturing (powder, liquid, and cream filling). Underlying technology is anchored by single-use manufacturing platforms that reduce contamination risk and enable rapid changeovers, complemented by in-house Chemistry and Microbiology quality-control laboratories that compress testing turnaround. The facility operates under cGMP with TGA, FDA, ISO 13485, and APVMA accreditations, allowing Sypharma to supply Australia and export markets. A separate Sykes Vet International sub-brand addresses veterinary pharmaceutical manufacturing under APVMA oversight.

The business model is B2B contract manufacturing: services are scoped and priced per engagement, with no publicly disclosed pricing. Revenue streams include full-service CDMO engagements, aseptic fill-and-finish, terminal sterilization, custom buffer and CIP solutions, IV fluid manufacturing, and non-sterile manufacturing. The company is privately held, founder/independently owned, with no disclosed institutional investors or funding rounds. Go-to-market is direct enterprise sales targeting biotech and vaccine developers, exemplified by long-standing partnerships with Vaxine Pty Ltd and the University of Queensland for COVID-19 vaccine candidates, a manufacturing collaboration with SCHOTT, and participation in the 2021 Genetis vaccine hub with Technovalia and BioNet.

Sypharma firmographics

Firmographics
Name
Sypharma
Legal name
Sypharma Pty Ltd
Website
https://sypharma.com.au
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Sypharma is an Australian specialty CDMO providing aseptic fill-and-finish, terminal sterilization, IV fluid, and single-use manufacturing services to innovative biotech developers across global regulated markets.
Ownership category
akta.pro rank

Sypharma industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Aseptic fill finish
  • Biopharmaceutical CDMO services
  • Vaccine manufacturing services
  • Intravenous fluid production

Where Sypharma is headquartered

Location

Headquarters

HQ city
Dandenong
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Sypharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Full-service CDMO providing integrated services including new drug development, early stage formulation, analytical development, scale-up, process validation, and commercial manufacturing for various dosage forms.
  2. Aseptic Fill & Finish: Manufacturing services for aseptic filling of pharmaceutical products including clinical trial injectables and commercial supplies.
  3. Terminal Sterilization: Terminal sterilization manufacturing services for pharmaceutical products requiring this production method.
  4. Custom Buffer & CIP Solutions: Custom formulation and cleaning solutions for pharmaceutical manufacturing.
  5. IV Fluid Manufacturing: Precision manufacturing of intravenous fluids for clinical and commercial use.
  6. Non-Sterile Manufacturing: GMP-grade excipient manufacturing for pharmaceutical and biopharmaceutical formulation, including powder, liquid and cream filling lines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Sypharma product offering

Product offering

Core offering

Sypharma is an Australian specialty contract development and manufacturing organization (CDMO) providing integrated pharmaceutical development and manufacturing services. Its core offerings include aseptic fill and finish, terminal sterilization, single-use manufacturing for clinical injectables, GMP intravenous (IV) fluid manufacturing, non-sterile excipient manufacturing, and custom buffer and CIP solutions, delivered to innovative biotech and vaccine developers across global markets.

Product overview

Sypharma is an Australian speciality contract development manufacturing organization (CDMO) offering integrated pharmaceutical development and manufacturing services. The portfolio includes core manufacturing services (Aseptic Fill & Finish, Terminal Sterilization, Single Use Manufacturing, Intravenous Fluid Manufacturing, Non-Sterile Manufacture), custom formulation solutions (Custom Buffer & CIP Solutions), veterinary products (Sykes Vet International), and in-house quality control laboratories. These services span the full drug development lifecycle from discovery through commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • Sykes Vet International: Veterinary pharmaceutical manufacturing services offered by Sypharma.

Products and services

  • Aseptic Fill & Finish Sterile aseptic filling and finishing services for pharmaceutical products, including clinical trial injectables and commercial supplies, conducted under cGMP conditions for biotech and pharmaceutical clients.
  • Terminal Sterilization Terminal sterilization manufacturing services for pharmaceutical products that require terminal sterilization as part of their production method, ensuring product safety and regulatory compliance.
  • Custom Buffer & CIP Solutions Custom formulation of buffer solutions and clean-in-place (CIP) solutions to support pharmaceutical manufacturing operations for client manufacturing processes.
  • Sykes Vet International Veterinary pharmaceutical manufacturing services operated under the Sykes Vet International sub-brand, covering GMP manufacturing of veterinary medicines and related products.
  • Single-Use Manufacturing Single-use manufacturing solutions for clinical trial injectables, offering flexible, contamination-free GMP production with reduced changeover time, lower contamination risk, cost savings, and faster time to market.
  • Intravenous Fluid Manufacturing GMP manufacture of intravenous (IV) fluids for clinical and commercial use, delivered via automated systems to ensure precision, sterility, and quality at scale for pharmaceutical clients.
  • Non-Sterile Manufacture GMP-grade non-sterile excipient manufacturing supporting pharmaceutical and biopharmaceutical formulation, with powder, liquid, and cream filling lines delivering consistent quality and regulatory compliance.

Quantifiable outcome

  • 8 million doses of SpikoGen vaccine safely delivered

Companies that use Sypharma

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Sypharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sypharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Vaxine Pty LtdcoreStrategic or Co-development Partner · 30 June 2020Partnership for manufacture of COVAX-19 and SpikoGen COVID-19 vaccines. Sypharma performed fill and finish of Vaxine's recombinant spike protein vaccine and manufactured Advax adjuvant products. First Australian-developed Covid-19 vaccine to enter human trials.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Sypharma competitors and assessment

Company assessment

Broad incumbents

  • Lonza: World's largest CDMO with broad aseptic fill-finish, mammalian and microbial biologics, and sterile manufacturing capabilities — competing with Sypharma for biotech and vaccine programs but at vastly larger scale.
  • PCI Pharma Services: Global CDMO with sterile fill-finish, clinical and commercial manufacturing, and packaging services — competing for similar biotech clients at larger scale.
  • Siegfried Holding: Swiss CDMO with aseptic fill-finish, terminal sterilization and API manufacturing — offers overlapping capabilities with Sypharma's sterile small-molecule drug product services.
  • Catalent: Large global CDMO offering aseptic fill-finish, sterile manufacturing and integrated development across biologics and small molecules — operates at significantly greater scale and geographic reach than Sypharma.
  • Recipharm: European CDMO with sterile fill-finish, biopharmaceuticals and vaccine manufacturing — comparable service portfolio with much larger international footprint.
  • Aenova Group: German-based CDMO with solid, semi-solid and sterile injectable manufacturing capabilities — overlaps with Sypharma's small-molecule drug product and aseptic fill-finish offerings.
  • Thermo Fisher Scientific (Patheon CDMO): Operates the Patheon CDMO network offering aseptic fill-finish, biologics and small-molecule drug product services — a broad incumbent competing with Sypharma for global biotech manufacturing programs.

Direct peers

  • Hovione: Portugal-headquartered specialty CDMO with strong aseptic fill-finish, terminal sterilization and integrated drug development services — directly comparable to Sypharma's core service mix across small-molecule and biologic injectables.
  • IDT Biologika: German CDMO specializing in vaccines, biotech and aseptic fill-finish — comparable to Sypharma on vaccine/biologics focus, cGMP manufacturing and pandemic-response capabilities.
  • Luina Bio: Australian cGMP CDMO offering biologics manufacturing, aseptic fill-finish and vaccine development — the closest domestic peer to Sypharma in scale, capability set and regulatory positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sypharma compliance and trust

Trust signal

Compliance4 records

Sypharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sypharma leadership team

Management profile

Number of profiles

Profiles1 record

Sypharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sypharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sypharma

What does Sypharma do?

Sypharma is an Australian specialty contract development and manufacturing organization (CDMO) providing integrated pharmaceutical development and manufacturing services. Its core offerings include aseptic fill and finish, terminal sterilization, single-use manufacturing for clinical injectables, GMP intravenous (IV) fluid manufacturing, non-sterile excipient manufacturing, and custom buffer and CIP solutions, delivered to innovative biotech and vaccine developers across global markets.

Is Sypharma a public or private company?

Sypharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sypharma founded?

Sypharma was founded in 2005. It employs 11 to 50 people.

Where is Sypharma based?

Sypharma is headquartered in Dandenong, Australia, in the Oceania region.

How does Sypharma make money?

Six revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are aseptic Fill & Finish, terminal Sterilization, custom Buffer & CIP Solutions, IV Fluid Manufacturing and non-Sterile Manufacturing.

Who are Sypharma's main competitors?

Broad incumbents on record are Lonza, PCI Pharma Services, Siegfried Holding, Catalent, Recipharm, Aenova Group and Thermo Fisher Scientific (Patheon CDMO). Direct peers are Hovione, IDT Biologika and Luina Bio.

Does Sypharma have an API?

No public API is recorded for Sypharma.

What industry is Sypharma in?

Sypharma's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales